Datamonitor, Feb 2011, Pages: 123
market.
- Thorough assessment of underlying commercial and clinical influencers shaping the Chinese hepatitisB market.
- In-depth discussion of novel hepatitisBpipeline candidates and assessment of their future
Datamonitor, Dec 2010, Pages: 126
. The majority of pipeline drugs are molecular targeted therapies (MTTs) and their incorporation into treatment will improve both patient outcomes and commercial potential.
Scope
Datamonitor, June 2010, Pages: 108
A and B populations by age for the US, Japan, France, Germany, Italy, Spain and the UK (%)
Figure: Current hepatitis C and human immunodeficiency virus prevalence among hemophilia and general populations
Datamonitor, Oct 2010, Pages: 196
key questions answered
- Get a comprehensive, insightfulcommercial overview of the vaccines market
- Learn about the strategies of the Big 5 players, their strengths, weaknesses, similarities
GBI Research, Feb 2011, Pages: 100
for all the types of Targeted Therapeutics (TT) are analyzed. The report provides comprehensive assessment of key pipeline therapies in the TT segment. The profiles of key promising molecules
Datamonitor, Nov 2011, Pages: 81
. The company’s most successful vaccines in China are its MMR, hepatitisB and A vaccines. Among domestic vaccine players, CNBG and Sinovac excel in terms of category 1 vaccine supply and strong R&D capacities
Datamonitor, March 2008, Pages: 123
of administration limits their use in certain areas. A high unmet need and defined target groups are required to gain commercial success. Pipeline products fulfilling these criteria have a greater chance
Datamonitor, March 2010, Pages: 279
-Examination of the gastrointestinal cancers pipeline with in-depth clinical and commercial profiles of Phase III candidates
-Seven major pharmaceutical market sales forecasts for Phase III pipeline products
Datamonitor, Dec 2008, Pages: 265
.
Scope
- Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types
- Seven major pharmaceutical market sales forecasts for Phase
Markets and Markets, Feb 2011, Pages: 264
delivery technologies.
REASONS FOR DOING THE STUDY:
More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body
Informa Healthcare, Jan 2007, Pages: 175
prostate, colon and lung cancers. There are also advanced candidates for influenza, malaria, tuberculosis, hepatitisB and HIV. Vaccines for rotavirus and meningitis A, diseases that kill vast numbers
Datamonitor, Dec 2008, Pages: 267
as the growth rate between 2006 and 2007 only reaching 8%.
Reasons to Purchase
- Get a comprehensive, insightfulcommercial overview of the vaccines market
- Learn about the strategies of the Big 5 players
GlobalData, Aug 2011, Pages: 46
and infectious diseases. The company's lead product, ZADAXIN, is marketed in over 30 countries for the treatment hepatitisB virus (HBV) and the hepatitis C virus (HCV), certain cancers and/or as a vaccine
PharmaVision, July 2009, Pages: 225
This cutting edge & insightful report can be used to interpret & assess the potential of RNAi-based medicines. It provides opinions & market projections to:
- assess the commercial potential
Espicom Business Intelligence Ltd, April 2009, Pages: 450
infections
Human immunodeficiency virus (HIV)
HepatitisB (HBV)
Hepatitis C (HCV)
Herpes
Current treatments
Bacterial infection
Table 4 Top ten antibiotics worldwide (based on 2007 sales)
Figure 9 US
